3 Things In Biotech, June 3: CAR-T Cell Therapy Revs Up Again – Seeking Alpha
Seeking Alpha |
3 Things In Biotech, June 3: CAR–T Cell Therapy Revs Up Again
Seeking Alpha News: Legend Biotech announced that the FDA has allowed JNJ’s Janssen to commence with a phase 1b/2 study involving its developmental CAR–T cell therapy called LCAR-B38M. This trial will enroll patients with relapsed or refractory multiple myeloma. |
|
Neuralstem’s NSI-566 stem cell therapy confers neurological improvement in spinal cord injury patients with complete …
GlobeNewswire (press release) Neuralstem Announces Publication of Data From First-In-Human Study of Human Neural Stem Cell Transplantation for Chronic Spinal Cord Injury -. – First cohort of four subjects with thoracic (T2-T12) ASIA-A grade spinal cord injury in the Phase I study … |
Drug Target Review |
CRISPR approach could limit toxicity of CAR-T therapy in AML
Drug Target Review A new approach may provide a new path towards treating acute myeloid leukaemia (AML) with CAR-T cells. To treat AML, investigators have to target a specific protein – CD33 – that’s also expressed on healthy cells, meaning the therapy cannot attack the … |
News-Medical.net |
Stem Cell Therapy for Alzheimer’s
News-Medical.net Stem cell treatments target to replace the damaged cells with healthy stem cells which can grow on their own, hence, creating new healthy brain cells. Because the transplant is usually autologous (using patient’s own body cells) in nature, there are … Taking Stem Cells to the BankPain News Network Global and Chinese Autologous Stem Cell Market Report by Manufacturers, Opportunities, Challenges, Drivers, Growth …Business Investor Market Analysis of Stem Cell Therapy for Diabetes and Related Conditions | Key Players Analysis and Forecast to 2021Exclusive Reportage Clean Technology –Expert Consulting –Technical Progress all 63 news articles » |